Coast to Coast Cures | Cure Cancer
home,page-template,page-template-full_width,page-template-full_width-php,page,page-id-15253,ajax_fade,page_not_loaded,,wpb-js-composer js-comp-ver-5.4.5,vc_responsive
The fight against cancer continues today.  Each of us has a connection to someone who has battled this terrible disease.  It’s time we find a cure, let that time to be now.  Coast to Coast Cures is a group created to support fundraising for the Leukemia & Lymphoma Society through their annual Man & Woman of the Year Fundraising Campaign.


The mission of The Leukemia & Lymphoma Society (LLS) is to: cure leukemia, lymphoma, Hodgkin’s disease and myeloma, and improve the quality of life of patients and their families.
Blood Cancer is the #3 Killer

Only lung and gastrointestinal cancers take more lives in the US each year. But, less than 1 in 10 new cancer diagnoses will be a blood cancer. And, there are many rare sub-types of leukemia’s, lymphomas and myelomas. Without donations from people like you, research into treatments would not be possible.

Leukemia is Most Common in Children

Since LLS began investing in research in 1949, the 5-year survival rate for children with acute lymphoblastic leukemia has improved from 5% to approximately 90%. Despite this improvement, leukemia causes more deaths than any other cancer among children, adolescents, and young adults.

LLS Research Has Been Utilized For Many Types of Cancers

Approximately 40% of new cancer therapies approved by the FDA between 2000 and 2017 were first approved for blood cancer patients and many are now helping patients with other serious diseases.  25% of more than 900 new cancer treatments in clinical testing by companies (as of June 2012) were first tested as treatments for blood cancer patients. These treatments include Chemotherapy, Bone Marrow Transplants, Molecular Targeting, and the first-ever FDA approved gene-therapy (Car-T).

Invest in Finding Cures

The Leukemia & Lymphoma Society (LLS) is the largest voluntary cancer research agency specifically focused on finding cures and better treatments for blood cancer patients. With the scope and scale to fund many projects at the same time, LLS supports hundreds of cancer scientists around the world and was  the first-ever non-profit to be awarded a Master Trial (Beat-AML).

Research Depends on You

Unlike commercial enterprises that consider blood cancers as “orphan diseases” with small markets and limited profit potential, LLS funds research based on medical need without regard to commercial return or market size. Every dollar invested comes from charitable support from concerned donors.

Extend Your Reach

LLS funds hundreds of promising researchers at leading cancer centers and universities worldwide. And since LLS has no campus or laboratories to maintain, your investment funds more research and less overhead than a donation made elsewhere.

Our Goal is to raise $100,000 annually between March 22nd and June 1st.


The Leukemia & Lymphoma Society’s Man & Woman of the Year (MWOY) campaign is a fundraising competition in communities across the U.S. in which participants vie for the title of Man or Woman of the Year. They raise funds for blood cancer research in honor of local children who are blood cancer survivors, the Boy & Girl of the Year. The titles are awarded to the men and women in each community who raise the most funds during the ten-week campaign; the top local fundraisers in the country also win the national titles.

Each year, in communities across the country, dynamic, passionate candidates engage in a spirited competition to earn The Leukemia & Lymphoma Society’s “Man & Woman of the Year” titles, by raising funds for blood cancer research. The candidates compete in honor of children who are local blood cancer survivors, the Boy & Girl of the Year. Every dollar counts as one vote, and the titles are awarded to the man and woman with the most votes at the end of ten weeks; the top local fundraisers in the country win the national titles.



Genevra Richardson is both a cancer awareness advocate and patient. She has served on the Leukemia & Lymphoma Society Board of Directors for the past 8 years and was the Board Chair for two years from 2012-2014. She Co-Chaired the inaugural year of the Man and Woman of the Year campaign in the Phoenix market in 2013 with her best friend Erica Anderson. Genevra was diagnosed with Stage 2 breast cancer in July of 2018 and is currently undergoing treatment.

She and her husband Jeff will celebrate 15 years of marriage this year, and they have two children – Beau, 8 and Reese, 5 and a new puppy, Penny Lane. Genevra is the President of GovGroup, a government relations firm located in Phoenix, Arizona. She has over twenty years of experience in politics and was voted “Best Female Lobbyist under 40” by the Arizona Capitol Times Best of the Capitol.

Genevra Richardson

2019 WOY Candidate

Antonio D Moore is a board certified registered nurse anesthetist. He spent 10 years working as a critical care nurse before returning to school to pursue a Master's Degree in Nurse Anesthesia from Midwestern University. He is the co founder of both M.A.C Anesthesia Services and IV Revival, a local, mobile IV hydration service.

Antonio Moore, CRNA

2019 MOY Candidate


Julian Herrera

Julian was diagnosed with Acute Lymphoblastic Leukemia (ALL) in 2015. At just 6 years of age he was facing the biggest fight of his life, and he has proven to be stronger than ever imagined. In July of 2017 he celebrated a HUGE milestone which concluded his treatment, and now to continue to strive!

Bella Hicks

Bella from 7 years ago during the height of her leukemia battle. Thanks to help from the LLS she is a happy, healthy and thriving 12 year old. Please consider a donation to help the mission of the Leukemia and Lymphoma Society to hep save other beautiful lives.



Coast to Coast Cures goal is to raise $1,000,000 for the LLS by 2025. 

Join The Fight!

Join The Fight!

Join our team to fundraise on behalf of the Leukemia & Lymphoma Society.



Attend an event benefiting the Leukemia & Lymphoma Society.